Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype
Abstract
Abstract Introduction: The Duffy null variant (genotype or phenotype) is associated with lower circulating absolute neutrophil counts (ANC) without increased risk for infection. It is found in ~66% of people identifying as Black or African American vs <1% of people of Asian or European ancestry. Many ANC reference intervals (RI) are not representative of the Duffy null population. There are no adult Duffy null WBC RI and no pediatric Duffy null ANC or WBC RI. Thus, we aimed to assess Duffy null ANC and WBC distributions as well as develop WBC and ANC RI for adults and pediatrics. Methods: Twenty-three sites across the United States collected samples with all sites excluding participants with conditions or medications that could impact ANC or WBC. Only Duffy null participants were included. Sex, race, ethnicity, age, sample collection type, practice setting, Duffy testing method, ANC, and WBC were recorded. The non-parametric method for determining lower limit of normal (LLN), upper limit of normal (ULN), and 90% confidence intervals (CI) around the limits was performed according to the Clinical and Laboratory Standards Institute guidelines. Specific ULN and LLN are not reported as these are preliminary data. The Mann-Whitney U test was used to compare sex and prior data; differences by age groups were assessed with Kruskal-Wallis test. Results: 316 participants 18+ years-old (y/o) were assessed of whom 62.3% (n=197) are female, 97.5% (n=308) identified as Black or African American, and 94.9% (n=300) identified as non-Hispanic. Median age was 47 y/o (IQR: 32-60.5). Median ANC was 2600/uL (IQR: 1860-3530; range: 400-7400); 28.6% (n=90) of participants had ANC <2000/uL, 13.6% (n=43) had ANC <1500/uL, and 2.5% (n=8) had <1000/uL. The 90% CI around the LLN was 810-1070/uL and 5570-7130/uL around the ULN. Consistent with prior data, there was a difference in median ANC by sex (male: 2400/uL; female: 2710/uL; p=0.02). There was no significant difference between this ANC data and previously published Duffy null ANC data (p=0.28). Median WBC was 5.4x109/L (IQR: 4.4-6.5; range: 2.10-11.64) with 4.1% (n=13) of participants with WBC <3.0x109/L. The 90% CI around the LLN is 3.68-4.30x109/L and 11.02-12.97x109/L around the ULN. 515 participants between 0-17 y/o were assessed with 51.8% (n=267) females, 94.8% (n=488) identified as Black or African American, and 94.0% (n=484) identified as non-Hispanic. Among pediatric participants, 56.8% (n=291) had ANC <2000/uL, 38.7% (n=198) had ANC <1500/uL, and 14.4% (n=74) had ANC <1000/uL. For those <1 y/o (n=29), median ANC was 950/uL (IQR: 840-1360; range: 111-3910). There are currently too few samples to predict ULN and LLN. Median WBC was 8.85x109/L (IQR: 7.03-10.16; range: 4.17-13.53). For those 1-5 y/o (n=143), median ANC was 1735/uL (IQR: 1100-2550; range: 207-5810) with a 90% CI around the LLN of 207-820/uL and 4020-5810/uL around the ULN. Median WBC was 6.72x109/L (IQR: 5.64-8.25; range: 3.68-12.97). For those 6-11 y/o (n=128), median ANC was 1590/uL (IQR: 1090-2470; range: 420-5490) with a 90% CI around the LLN of 420-910/uL and 4340-5490/uL around the ULN. Median WBC was 5.42x109/L (IQR: 4.45-6.70; range: 2.80-10.50). For those 12-17 y/o (n=215), median ANC was 2190/uL (IQR: 1460-2930; range: 204-5850) with a 90% CI around the LLN of 540-930/uL and 4350-5510/uL around the ULN. Median WBC was 5.06x109/L (IQR: 4.26-6.20; range of 2.04-9.91). There is a significant difference in ANC by age category (p<0.0001). Conclusion: This is the first report of healthy pediatric Duffy null ANC and WBC data and the first large-scale verification of adult Duffy null ANC and WBC data. Final RI are expected in September 2025. Among adults with the Duffy null phenotype, ANC LLN are likely between 810-1070/uL. Pediatric ANC LLN are likely as low as 207-820/uL (1-5 y/o), 420-910/uL (6-11 y/o), and 540-930/uL (12-17 y/o). These findings redefine “normal” as a significant proportion of healthy participants have ANC or WBC below current RI or below thresholds typically defined as disease. Limitations include heterogeneous sample populations and collection methods. Future analyses will assess differences between collection sites or methods. Ultimately, this work lays the foundation for a more scientifically sound and equitable approach to medical care by ensuring that RI accurately reflects health for the entire community. Healthcare systems are strongly encouraged to adopt Duffy null-specific ANC and WBC RI.
Article Details
Authors (55)
Lauren Merz
5Dana-Farber Cancer Institute, Medical Oncology, Boston, United States
Gilles Attipoe
4St. Peter's University Hospital, New Brunswick, United States
Christina Barriteau
5Lurie Children's Hospital, Chicago, United States
Michael Blechner
6University of Connecticut, Farmington, United States
Eric Burks
1Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, United States
Cecelia Calhoun
3Yale School of Medicine, Pediatrics, New Haven, United States
Sally Campbell Lee
9University of Illinois Chicago, Chicago, United States
Vivian Chang
3University of California Los Angeles Health, Los Angeles, United States
Stella Chou
2Children's Hospital of Philadelphia, Pediatrics, Philadelphia, United States
Adam Cuker
3Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
Emmanuel Fadeyi
13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States
Warren Fingrut
1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States
Victoria Forbes
2University of Connecticut, Hematology and Oncology, Farmington, United States
Ivo Francischetti
15Johns Hopkins University Hospital, Baltimore, United States
Vijayakrishna Gadi
9University of Illinois Chicago, Chicago, United States
Richard Godby
1Mayo Clinic, Department of Internal Medicine, Rochester, United States
Lucy Godley
4Northwestern University, Chicago, United States
Abraham Haimed
11Children's Hospital of Philadelphia, Philadelphia, United States
Hyojeong Han
Department of Biomedical Engineering, Hanyang University
Richard Haspel
19Beth Israel Deaconess Hospital, Boston, United States
Chibuzo Ilonze
1University of Alabama at Birmingham, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Heersink School of Medicine, Birmingham, United States
Cyril Jacquot
18Children's National Hospital, Washington, D.C., United States
Peng Ji
Justin Juskewitch
16Mayo Clinic, Rochester, United States
Matthew Karafin
1University of North Carolina at Chapel Hill, Pathology and Laboratory Medicine, Chapel Hill, United States
Kimberly Klein
14The University of Texas MD Anderson Cancer Center, Houston, United States
Nicole Kucine
14Department of Pediatrics, Weill Cornell Medicine, New York, United States
Priya Kumar
Margarita Kushnir
24Banner Health, Phoenix, United States
David Levitz
1Montefiore Einstein Comprehensive Cancer Center, Bronx, United States
Michael Lewis
Geling Li
20University of Alabama at Birmingham, Birmingham, United States
Zhen Mei
10University of California Los Angeles, Los Angeles, United States
Sabrina Racine Brzostek
6Weill-Cornell Medical College, Medicine, New York City, United States
Gary Rose
26Nemours Children's Hospital, Wilmington, United States
Corinna Schultz
26Nemours Children's Hospital, Wilmington, United States
Alexa Siddon
Christine Sillings
27Norton Healthcare, Louisville, United States
John Mark Sloan
2Boston Medical Center, Boston, United States
Amy Soni
13Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, United States
Don Stevens
3Norton Cancer Institute, Louisville, United States
Charlotte Story
1Johns Hopkins University School of Medicine, Division of Hematology, Department of Medicine, Baltimore, United States
James Szymanski
25Montefiore Medical Center and Albert Einstein College of Medicine, New York City, United States
Clifford Takemoto
21St. Jude Children's Research Hospital, Memphis, United States
Alexis Thompson
Rahma Warsame
1Mayo Clinic, Rochester, United States
Angela Weyand
4Department of Pediatrics, University of Michigan Medical School, Ann Arbor, United States
Samuel Wilson
Nibal Zaghloul
4St. Peter's University Hospital, New Brunswick, United States
Yadashe Belay
28American Society of Hematology, Washington, D.C., United States
Aliza Fink
8National Organization for Rare Disorders, Quincy, United States
Patricia Frustace
28American Society of Hematology, Washington, D.C., United States
Jamie Tyson
28American Society of Hematology, Washington, D.C., United States
Nathalie Van Havre
1American Society of Hematology, Washington, United States
Maureen Okam Achebe
17Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA